Navigation Links
Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
Date:12/13/2007

hem expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs, and participate in many of the new cancer-related clinical research studies. US Oncology also provides a broad range of services to pharmaceutical manufacturers, including product distribution and informational services such as data reporting and analysis.

According to the company's last quarterly earnings report, US Oncology is affiliated with 1,164 physicians operating in 443 locations, including 91 radiation oncology facilities in 39 states.

About US Oncology Research Network

The US Oncology Research Network is an established community-based research operation specializing in all phases of cancer clinical trials. The research network currently has 500 physicians actively enrolling patients, 77 research sites, and is currently involved in more than 60 open research trials. The network has contributed to the development of 24 of 30 of the latest cancer-fighting drugs approved by the Food and Drug Administration for use. Since 1993, more than 32,000 patients have participated in clinical trials managed by US Oncology network practices. For more information, visit the "Research" section under "Our Services" on the company's Web site, http://www.usoncology.com.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contact: Noelle Boyd

sanofi-aventis


'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
2. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
3. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
4. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
5. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
6. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
7. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
8. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
9. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
10. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
11. Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... MONTREAL and YONGIN, South Korea ... with great pride that Green Cross Biotherapeutics Inc. (GCBT) ... will be located on the Montreal Technoparc,s Saint-Laurent Campus. ... green field investment projects in Canada ... construction of the first intravenous immunoglobulin (IVIG) and albumin ...
(Date:6/1/2015)... 2015 About Bio-alcohols Bio-alcohols ... or cellulose. Bio-alcohols are primarily used in the transportation ... replacement for gasoline in cars. Technavio,s analysts forecast the ... 9 percent over the period 2014-2019. ... be segmented into five: transportation, infrastructure, medical, and others. ...
(Date:6/1/2015)... June 1, 2015 Research ... addition of the "Global PDT Machine Industry ...        (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... is a professional and in-depth study on the ... report provides a basic overview of the industry ...
(Date:6/1/2015)... , May 29, 2015 Research ... addition of the "Global Bioinformatics Market 2015-2019" ... analysts forecast the global bioinformatics market to grow ... 2014-2019. Bioinformatics is a field of science ... consists of information stored in DNA form and ...
Breaking Biology Technology:Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Global Bio-alcohols Market 2015-2019 2Global PDT Machine Industry Report 2014 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 3
... Aug. 2, 2011 Cephalon, Inc. (Nasdaq: CEPH ... million, a 2 percent increase compared to net sales of ... per common share for the period was $1.54 compared to ... and certain other items, adjusted net income for the second ...
... 2011 Enzymatics, Inc., ( www.enzymatics.com ) a leading ... Boston Chamber of Commerce with a "Top 10 Small ... Honorees include dynamic small and high growth businesses in ... excellence, product innovation, and social responsibility.  An awards luncheon ...
... N.Y. Every year, millions of people contend with ... their pain, Cornell University engineers in Ithaca and doctors ... City have created a biologically based spinal implant that ... Lawrence Bonassar, Ph.D., associate professor of biomedical engineering ...
Cached Biology Technology:Cephalon Reported Financial Results for the Second Quarter of 2011 2Cephalon Reported Financial Results for the Second Quarter of 2011 3Cephalon Reported Financial Results for the Second Quarter of 2011 4Cephalon Reported Financial Results for the Second Quarter of 2011 5Cephalon Reported Financial Results for the Second Quarter of 2011 6Cephalon Reported Financial Results for the Second Quarter of 2011 7Cephalon Reported Financial Results for the Second Quarter of 2011 8Cephalon Reported Financial Results for the Second Quarter of 2011 9Cephalon Reported Financial Results for the Second Quarter of 2011 10Cephalon Reported Financial Results for the Second Quarter of 2011 11Cephalon Reported Financial Results for the Second Quarter of 2011 12Enzymatics Honored With a Top 10 Small Business of the Year Award 2In the battle to relieve back aches, Cornell researchers create bioengineered spinal disc implants 2In the battle to relieve back aches, Cornell researchers create bioengineered spinal disc implants 3
(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) ... Recognition Market by Solution, by Software, by Hardware, ... report to their offering. The ... become more efficient and cost effective. This has ... from the commercial sector. The development of 3D ...
(Date:5/22/2015)... 22, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... be ending its promotional pricing and making the Wocket generally ... Laurence Savin , Head of Marketing said, "We,ve extended the ... the end of May. To get your wocket at this ... open the store on June 1, you,ll receive a unique ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. (NASDAQ: ... its wholly owned subsidiary, 3D-ID LLC, a company engaged ... Battelle for the biometrics technology portion of the recently ... from the Department of the Army. 3D-ID ... developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... recently discovered that a chemical chain reaction that controls ... could mean the difference between normal growth and cancer. ... Cell, describes how organs can grow uncontrollably huge and ... This chain reaction, a domino-like chain of events ...
... HONOLULU, Sept. 20 Women with low levels of vitamin ... a study led by the University of Pittsburgh Graduate School ... meeting of the American Society for Bone and Mineral Research ... professor of epidemiology, and colleagues evaluated patient data on 400 ...
... Nile virus first struck New York City in 1999, ... public health officials alike, showing that even affluent, urban ... virus has been widely studied, there is still little ... between urban and rural areas. Assistant professor at ...
Cached Biology News:Controlling for size may also prevent cancer 2Low vitamin D linked to higher risk of hip fracture 2UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC 2
Nestin, Human...
Ezrin/Radixin/Moesin Antibody...
... Taura Syndrome Virus Coat Protein ... tested applications). ... MNDIPITNQN VVLSKNVTDN LFEVQDQALI ESLSRDVLLH NDSWTSSDDE ... terminal amino acids 25/100 of ...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
Biology Products: